EXCHANGE
Company
Nano-H S.A.S.
This company is a member of Lyonbiopole
General company information
Address : 2 place de l'Europe Bat. A Parc d'activite GVIO
Zip code : 38070
City : Saint Quentin Fallavier
Incorporated in : 2004/12/27
Number of employees : 6
Turnover : €0,5M (in 2010)Main activity : Nano-H develops and uses innovative technology for manufacturing new materials, nanoparticle hybrids. Innovative company, it offers service and material for high technology industries and research laboratories: phosphors, counterfeiting, plotter, medical imaging and bio-sensors, biological detection and in-vivo or in vitro. Products are high quality by their size and their chemical and physical adaptability. The materials are defined by specific nanoparticle hybrids with size and surface adaptable to graft hybrid molecules : organic (fluorpohores) or biological. The many additional properties of these nano-hybrid : optical, magnetic, radio-active, ensure a real multifunctional tool. They are also new contrast agents (medical imaging), therapeutic agents (oncology) and tracers in the fields of cell labeling and tracking and anti-counterfeit marking mass or unit.
Incubator : Yes (Crealys)
Subsidiary of a group : No
Prize winner for innovative start-up : Yes (Creaction & Development, 2004)
Innovative company (FCPI) : No
Other status (JEI, JEU, ...) : Yes
Website : www.nano-h.com
Funding
Looking for funding : No
R&D projects accredited by Lyonbiopole and funded
APTAPROBE : Nanohybrids grafted with aptamer targeting tumoral tissue for multimodal detection and therapy
Funding : ANR (ANR 2008 Biotecs)
Company role in the project : Leader
CAPTCODE : Labelless diagnostic lab on chip, use of hybrid luminescent nanoparticles
Funding : ANR (ANR 2005 NANO)
Company role in the project : Partner
NANOGADO : Rare earth oxyde nanoparticles : new agents for diagnostic and combined therapy
Funding : ANR (ANR 2005 NANO)
Company role in the project : Partner
THERANEAN : Therapy through Neutron-Activated Nanoparticles
Funding : FUI (FUI AAP7)
Company role in the project : Partner
Company contact
First name : Cedric
Last name : Louis
Position : President
Email : c.louis@nano-h.com
Phone : +33 4 74 945 346
First name : Laurence
Last name : Marmuse
Position : R&D Engineer
Email : contact@nano-h.com
Phone : +33 4 74 945 346
Company segmentation
Business model
Service provider - Scientific, Product developer - Other health
Value chain
Research, Manufacturing, Preclinical
Activities
Diagnostics / Analysis method, Cell therapy, Preclinical trials, Nanotechnology, Other
Application fields
Animal health, Human health, Infectiology, Orphan diseases, Genetic / Rare diseases, Cancer
Activities
Presentation of company's activity
Nano-H is an innovative company aimed at high technology industries and research laboratories, users of nanoparticles: phosphors, counterfeiting, plotter, medical imaging and bio-sensors, biological detection and in-vivo or in vitro. It offers its services to manufacturing and marketing of its products based on nanoparticles. They meet the needs of high quality by their size and their chemical and physical adaptability.
Nano-H develops specific materials for its partners based on functional nano-objects best suited to their specific applications.
The specific products that Nano-H offers are defined by hybrid nanoparticles: size and surface functionality with adaptable by grafting hybrid molecules: organic (fluorpohores) or biological. The many additional properties of these nano-hybrid: optical, magnetic, radio-active, make a real multifunctional tool available, with significantly improved performance in many sectors of industry and nanotechnology. These nano-hybrids can offer and market analysis of biological probes of high sensitivity capable of lowering the threshold of current detection. They are also new contrast agents for the imaging industry medical potential of therapeutic agents capable of penetrating the market for treatment of cancer, probes for labeling and for cell therapy, and tracers for in vivo consider targeting and active treatment for localized tumors. Several products are currently under preclinical evaluation. Finally we propose a new generation of tracers in the field of anti-counterfeit marking mass or unit.
